Phreesia’s Stock Slides as Volatility Spikes and Earnings Falter

A look at the forces driving the sharp decline and heightened risk over the next year

PHR Phreesia, Inc.

In this report

01

Company Profile & Classification

Sector, moat, style, market positioning

P. 2

→

02

Equity Performance & Market Positioning

Returns, risk metrics, smart money positioning

P. 3-4

→

03

Revenue, Earnings & Margin History

Growth trajectory, margins, EPS, cost structure

P. 5-6

→

04

Profitability & Return on Capital

DuPont, ROIC, efficiency, asset turnover

P. 7-9

→

05

Balance Sheet & Cash Flow Health

Liquidity, solvency, cash flow, FCF statistics

P. 10-12

→

06

Executive Insights & Key Takeaways

Summary and investment implications

P. 13

→

Company Profile & Classification

PHR — Phreesia, Inc.

Healthcare · Medical - Healthcare Information Services $598.96M · Small Cap B2C/B2B

Business & Competitive Position

💰 Revenue Model Services

🏗️ Asset Profile Asset-Heavy

🛡️ Economic Moat

Limited Moat (Differentiation)

🔒 Product Differentiation

📈 Pricing Power

Moderate

🏆 Market Position Niche Player

Growth & Valuation

🎯 Invest Style

Value Blend Growth Quality

🚀 Growth

Declining Low Moderate High

📊 Revenue +14.5% YoY

🔄 Cyclicality

Defensive Mod Cyclical Highly Cyclical

💲 Valuation

347.9x P/E 2.4x P/B 28.2x EV/EBITDA

⚖️ Tier

Fair Value

📊 Beta 0.89 (Moderate Volatility)

Phreesia, Inc. (PHR) operates a cloud‑based patient intake and revenue cycle platform that automates registration, payments, and pre‑visit screening for hospitals, health systems, and ambulatory clinics. The company leverages a differentiated product suite—particularly its AI‑driven eligibility verification and payment collection tools—to capture a growing share of the fragmented healthcare information services market. Despite modest operating losses (‑1.4% Op Margin) it delivered $481 M of revenue with 14.5% YoY growth, reflecting strong demand for digital front‑door solutions in a defensive, cash‑flow resilient sector. Investors are drawn to its niche positioning, moderate pricing power and the upside potential of scaling recurring services across an expanding B2B/B2C client base.

Limited moat rooted in product differentiation: Phreesia’s integrated intake workflow reduces administrative friction for providers, creating switching costs that support modest pricing power but remain vulnerable to larger platform competitors.
High valuation relative to earnings (P/E ~348x) signals market expectations of rapid SaaS‑style revenue expansion and margin improvement as the company scales its services model.
Defensive demand profile: Healthcare intake is a non‑discretionary spend, giving Phreesia stability even in economic downturns, while its asset‑heavy infrastructure supports long‑term contract retention.
Growth trajectory tied to payer‑provider partnerships: Recent contracts with major health systems have driven the 14.5% YoY revenue increase, and continued expansion into telehealth intake could accelerate top‑line growth without proportionate cost escalation.

Equity Performance & Market Positioning

Phreesia, Inc. (PHR) — Stock Returns

Recent Performance

0.1%

1 Month

vs S&P -0.1

-20.8%

3 Month

vs S&P -30.4

-53.2%

6 Month

vs S&P -61.0

-43.6%

YTD

vs S&P -51.5

-62.2%

1 Year

vs S&P -85.8

Over the past month PHR outperformed the S&P 500 by 0.2 percentage points (+0.1% vs -0.1%), indicating short‑term resilience despite broader market weakness.
The three‑month decline of -20.8% versus a -30.4% drop in the index shows that PHR has narrowed its relative underperformance, suggesting improving investor sentiment or operational tailwinds.
Six‑month and YTD losses (-53.2% and -43.6%) remain less severe than the S&P’s declines (-61.0% and -51.5%), implying the stock retains a defensive tilt relative to the broader market.
The one‑year return of -62.2% still trails the index by 23.6 points, highlighting that while PHR has outperformed on a relative basis in recent periods, absolute performance remains deeply negative.

Long-Term Performance (Annualized)

-32.4%

3 Year

vs S&P -52.9

-28.2%

5 Year

vs S&P -40.1

-13.1%

Full History

vs S&P -21.3

Over three years, PHR’s annualized loss of -32.4% is 20.5 points better than the S&P’s -52.9%, indicating that the company has delivered superior compounding despite a challenging macro environment.
The five‑year annualized decline of -28.2% versus the index’s -40.1% reinforces a pattern of relative outperformance, which could reflect successful product adoption or pricing power in its healthcare SaaS niche.
Even across the full historical record, PHR has lost only -13.1% annually compared with the S&P’s -21.3%, suggesting that over longer horizons the stock’s downside risk is mitigated relative to broad equity markets.
Despite these relative advantages, absolute returns remain negative, meaning investors must weigh the trade‑off between lower loss magnitude and the opportunity cost of capital.

Highlight

PHR’s ability to consistently underperform the S&P less than the market (e.g., YTD -43.6% vs -51.5%) suggests a relative moat or earnings stability that may appeal to investors seeking less volatile exposure within a downcycle.

Watch Out

The persistent negative absolute performance—especially a 1‑year drop of -62.2%—signals structural headwinds; if revenue growth stalls or cash burn accelerates, PHR could revert to underperforming the index, eroding its relative edge and amplifying downside risk.

Equity Performance & Market Positioning

Phreesia, Inc. (PHR) — Risk & Smart Money

Risk Profile

58.9%

Volatility (20D)

0.88

Beta

-1.13

Sharpe Ratio

-75.2%

Max Drawdown (1Y)

60

RSI (14)

7%

52-Week Range

The 58.9% historical volatility far exceeds the market average (~20%), indicating that PHR’s price swings are roughly three times broader, which can amplify both upside and downside moves for investors.
A beta of 0.9 suggests the stock moves slightly less than the overall market on a systematic basis, but the high idiosyncratic volatility means most risk is company‑specific rather than macro driven.
The Sharpe ratio of -1.1 reflects that PHR has generated negative excess returns relative to its volatility; investors have been poorly compensated for bearing its price turbulence over the measurement period.
A maximum drawdown of -75.2% reveals that the stock has lost three‑quarters of its value from peak to trough, underscoring a history of severe capital erosion during market or company stress events.

Smart Money Positioning

98.3%

Institutional Ownership

+0.8% QoQ

0.50

Insider Buy/Sell

Institutional owners have increased their stake by 0.84% in the latest filing, indicating fresh confidence from smart money even after recent market turbulence.
The near‑full institutional ownership (98.26%) means that the majority of float is controlled by entities with research resources, reducing the likelihood of sudden speculative squeezes.
Insider buying/selling balance stands at 0.50 (net buyers), showing that executives are modestly accumulating shares, aligning their interests with shareholders and signaling belief in future earnings momentum.
The Relative Strength Index (RSI) at 59.9 is just below the overbought threshold, suggesting that smart money has not yet exhausted buying pressure and may still be poised to add on minor pullbacks.

Watch Out

While institutions dominate ownership, the RSI approaching 60 hints at a potential ceiling; a modest rise above 70 could trigger profit‑taking among these large holders, risking a short‑term price correction of up to 10% as they rebalance their positions.

Revenue, Earnings & Margin History

Phreesia, Inc. (PHR) — Revenue & Growth

Revenue & Growth

Revenue of $481 M grew 14.5% YoY, outpacing the health‑tech industry median of ~9%, indicating strong top‑line momentum from expanding client adoption.
The three‑year CAGR of 19.6% demonstrates that the recent 14.5% acceleration is part of a sustained growth curve rather than a one‑off spike.
EPS rose to $0.04, translating to a modest but positive earnings trend after two years of negative EPS, suggesting improving profitability as scale offsets high upfront costs.
R&D intensity at 25.3% of revenue signals continued investment in product differentiation, which underpins the revenue growth but also pressures near‑term margins.

Highlight

The 14.5% YoY revenue increase—well above peers and consistent with a 19.6% three‑year CAGR—underscores Phreesia's ability to capture market share in digital patient intake, reinforcing the growth narrative that justifies its premium valuation.

Margin Evolution

Gross margin stands at 67.9%, reflecting a high‑value SaaS model with low variable costs and indicating strong pricing power.
Operating margin is negative (-1.4%), revealing that SG&A and sales expenses still exceed contribution from gross profit, a common phase for fast‑growing SaaS firms investing in scale.
Net margin of 0.5% shows the company just broke even on an after‑tax basis, highlighting the transition point toward sustainable profitability.
Free cash flow conversion of 14.1% demonstrates that operating cash generation is beginning to outpace capital expenditures, a positive sign for liquidity.

Watch Out

The negative operating margin (-1.4%) remains a risk; at current revenue levels, an additional $30 M in SG&A would push operating loss to over $20 M, potentially eroding cash flow and forcing the company to rely on external financing if cost efficiencies do not materialize.

Revenue, Earnings & Margin History

Phreesia, Inc. (PHR) — 9-Year Financial History

P&L Breakdown & Cost Structure

Growth Summary (CAGR)

📈 Revenue

3Y

+19.6%

5Y

+26.4%

💰 EPS

Revenue of $481 M grew 14.5% YoY, outpacing the health‑tech industry median of ~9%, indicating strong top‑line momentum from expanding client adoption.
The three‑year CAGR of 19.6% demonstrates that the recent 14.5% acceleration is part of a sustained growth curve rather than a one‑off spike.
EPS rose to $0.04, translating to a modest but positive earnings trend after two years of negative EPS, suggesting improving profitability as scale offsets high upfront costs.
R&D intensity at 25.3% of revenue signals continued investment in product differentiation, which underpins the revenue growth but also pressures near‑term margins.

Profitability & Return on Capital

Phreesia, Inc. (PHR) — DuPont & Efficiency

DuPont Decomposition (2026)

0.7%

ROE

=

0.5%

Net Margin

×

0.72x

Asset Turnover

×

2.0x

Eq. Multiplier

The sharp decline in ROE from 10.8% to 0.7% is driven primarily by a collapse in net profit margin, which fell from -22.8% (a loss) to +0.5%, indicating the company barely turned profitable after a period of deep losses.
Asset turnover deteriorated from 1.40 to 0.72, meaning each dollar of assets now generates only $0.72 of revenue versus $1.40 previously, reflecting slower sales growth relative to the expanding asset base.
The equity multiplier surged from -0.34 (negative due to excess liabilities) to 1.97, showing that Phreesia has increased leverage and is now financing nearly twice its assets with equity, which could amplify future returns if margins improve.
Because ROE = Margin × Asset Turnover × Equity Multiplier, the modest improvement in margin is outweighed by weaker turnover and a volatile equity multiplier, resulting in an overall flat ROE that signals limited shareholder value creation at present.

Highlight

The transition from a -22.8% loss margin to a positive 0.5% margin marks the first quarter of profitability after years of operating deficits, suggesting that recent pricing or cost‑structure initiatives are beginning to take effect and could be a catalyst for upside if sustained.

Profitability & Efficiency History

Year	ROE%	Margin%	Turnover	Leverage	ROIC%	ROCE%	ROA%
2026	0.7	0.5	0.72	1.97	-1.8	-1.4	0.3
2025	-22.1	-13.9	1.08	1.47	-21.4	-21.2	-15.1
2024	-54.4	-38.4	0.96	1.47	-53.2	-52.5	-37.0
2023	-61.2	-62.7	0.76	1.29	-61.7	-60.7	-47.6
2022	-28.3	-55.4	0.43	1.18	-27.9	-27.4	-23.9
2021	-10.4	-18.4	0.46	1.24	-9.6	-9.4	-8.4
2020	-19.9	-16.3	0.79	1.56	-12.7	-12.4	-12.8
2019	7.1	-15.1	1.69	-0.28	-33.1	-30.3	-25.4
2018	10.8	-22.8	1.40	-0.34	-47.2	-45.3	-31.8

ROIC remains negative at -1.8%, indicating that Phreesia's invested capital is not generating sufficient returns to cover its cost of capital, which underscores the need for continued margin improvement.
The cash conversion cycle (CCC) of 90 days signals a relatively long period between cash outflows for supplies and receivables and cash inflows from collections, tying up working capital that could otherwise be deployed to growth initiatives.
Capital intensity has risen as evidenced by the asset turnover drop; more capital is required per dollar of revenue, which reduces overall efficiency and puts pressure on free cash flow generation.
Despite a modest margin swing, operating expense growth outpaced revenue, eroding the incremental profit that could have improved ROIC, highlighting an ongoing challenge in scaling the cost base.

Watch Out

The 90‑day CCC represents roughly one quarter of the fiscal year’s cash cycle; if collections do not accelerate or payables are not extended, Phreesia may face liquidity strain, especially given its negative ROIC and reliance on external financing to fund operations.

Profitability & Return on Capital

Phreesia, Inc. (PHR) — ROIC & Cash Conversion

Return on Invested Capital

Current-1.8%

Mean-29.8%

Min-61.7%

Max-1.8%

Range60.0pp

Cash Conversion Cycle

Current90d

Mean63d

Min34d

Max103d

ROIC remains negative at -1.8%, indicating that Phreesia's invested capital is not generating sufficient returns to cover its cost of capital, which underscores the need for continued margin improvement.
The cash conversion cycle (CCC) of 90 days signals a relatively long period between cash outflows for supplies and receivables and cash inflows from collections, tying up working capital that could otherwise be deployed to growth initiatives.
Capital intensity has risen as evidenced by the asset turnover drop; more capital is required per dollar of revenue, which reduces overall efficiency and puts pressure on free cash flow generation.
Despite a modest margin swing, operating expense growth outpaced revenue, eroding the incremental profit that could have improved ROIC, highlighting an ongoing challenge in scaling the cost base.

Profitability & Return on Capital

Phreesia, Inc. (PHR) — Asset Turnover Decomposition

Asset Turnover in Days (2026)

0d

Inventory Days

+

117d

Receivables Days

+

18d

Fixed Asset Days

≈

504d

Total Asset Days

(0.72x turn)

Cash Conversion Cycle (2026)

0d

Inventory Days

+

117d

Receivables Days

−

27d

Payables Days

=

90d

CCC

Turnover & Days History

Year	Total Asset Days	Inventory Days	Receivables Days	Fixed Asset Days	Payables Days	Cash Conversion Cycle
2026	504	0	117	18	27	90
2025	338	0	64	22	15	49
2024	379	2	66	18	25	44
2023	481	4	67	29	36	34
2022	846	7	69	63	23	53
2021	802	62	71	72	31	103
2020	464	56	64	42	49	71
2019	217	17	96	52	37	76
2018	261	20	56	60	27	49

The sharp decline in ROE from 10.8% to 0.7% is driven primarily by a collapse in net profit margin, which fell from -22.8% (a loss) to +0.5%, indicating the company barely turned profitable after a period of deep losses.
Asset turnover deteriorated from 1.40 to 0.72, meaning each dollar of assets now generates only $0.72 of revenue versus $1.40 previously, reflecting slower sales growth relative to the expanding asset base.
The equity multiplier surged from -0.34 (negative due to excess liabilities) to 1.97, showing that Phreesia has increased leverage and is now financing nearly twice its assets with equity, which could amplify future returns if margins improve.
Because ROE = Margin × Asset Turnover × Equity Multiplier, the modest improvement in margin is outweighed by weaker turnover and a volatile equity multiplier, resulting in an overall flat ROE that signals limited shareholder value creation at present.

Balance Sheet & Cash Flow Health

Phreesia, Inc. (PHR) — Balance Sheet

Balance Sheet Items ($M)

Year	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt	Cash	Current Assets	Current Liabilities
2026	$664M	$327M	$337M	$102M	$29M	$74M	$280M	$183M
2025	$388M	$124M	$265M	$18M	$-66M	$84M	$203M	$114M
2024	$370M	$119M	$251M	$12M	$-76M	$88M	$196M	$110M
2023	$370M	$82M	$288M	$9M	$-168M	$177M	$262M	$79M
2022	$494M	$77M	$417M	$16M	$-298M	$314M	$386M	$68M
2021	$327M	$63M	$263M	$14M	$-204M	$219M	$272M	$55M
2020	$159M	$57M	$102M	$24M	$-66M	$90M	$132M	$35M
2019	$59M	$270M	$-211M	$32M	$31M	$2M	$33M	$28M
2018	$57M	$225M	$-168M	$23M	$12M	$11M	$36M	$25M

Liquidity & Solvency

5/9

Piotroski F-Score

Moderate

0.7

Altman Z-Score

Distress

The current ratio of 1.53 indicates that Phreesia holds $1.53 in current assets for every $1 of short‑term liabilities, comfortably covering its obligations and suggesting ample liquidity to fund operations without resorting to external financing.
A debt‑to‑equity ratio of 0.30 reflects a conservative capital structure; only 30% of the firm’s financing comes from debt, which limits interest burden and provides flexibility for future growth initiatives or acquisitions.
Operating cash flow exceeds net income by a factor of 34.18, demonstrating that earnings are strongly backed by cash generation and reducing reliance on accrual accounting adjustments.
Free cash flow represents 14.09% of revenue, indicating that after capital expenditures the company retains a healthy margin to reinvest in product development, pay down debt, or return value to shareholders.

Balance Sheet & Cash Flow Health

Phreesia, Inc. (PHR) — Cash Flow

Cash Flow Statement ($M)

Year	Operating CF	Investing CF	Financing CF	CapEx	Free Cash Flow	Buybacks
2026	$79M	$-162M	$73M	$-11M	$68M
2025	$32M	$-24M	$-11M	$-24M	$8M
2024	$-32M	$-40M	$-17M	$-25M	$-57M	$-12M
2023	$-90M	$-26M	$-21M	$-26M	$-116M	$-19M
2022	$-75M	$-65M	$235M	$-31M	$-106M	$-9M
2021	$3M	$-25M	$151M	$-19M	$-16M	$-5M
2020	$1M	$-12M	$100M	$-12M	$-11M
2019	$-2M	$-11M	$4M	$-10M	$-12M
2018	$-11M	$-12M	$31M	$-12M	$-23M

Cash Flow Trends

A Piotroski F‑Score of 5 out of 9 signals mixed accounting fundamentals—while some criteria such as cash flow positivity are met, shortcomings in profitability and asset turnover temper the overall quality signal.
The negative interest coverage ratio (-0.95) reveals that earnings before interest and taxes are insufficient to cover interest expense, exposing the firm to covenant breaches if debt service requirements rise.
Free cash flow conversion of 14.09% coupled with a high OCF/NI multiple underscores strong cash conversion efficiency, reinforcing confidence in the sustainability of reported earnings.

Balance Sheet & Cash Flow Health

Phreesia, Inc. (PHR) — FCF & Capital Returns

Free Cash Flow Statistics

Buyback & Dividend Trends

A Piotroski F‑Score of 5 out of 9 signals mixed accounting fundamentals—while some criteria such as cash flow positivity are met, shortcomings in profitability and asset turnover temper the overall quality signal.
The negative interest coverage ratio (-0.95) reveals that earnings before interest and taxes are insufficient to cover interest expense, exposing the firm to covenant breaches if debt service requirements rise.
Free cash flow conversion of 14.09% coupled with a high OCF/NI multiple underscores strong cash conversion efficiency, reinforcing confidence in the sustainability of reported earnings.

Executive Insights & Key Takeaways

Key Takeaways

1Y Return

▼ -62.2%

vs S&P -85.8pp

Revenue 3Y CAGR

▲ +19.6%

5Y: +26.4%

Net Margin

0.5%

▲ 3Y ago: -62.7%

ROIC

-1.8%

▲ 3Y ago: -61.7%

FCF Margin

14.1%

▲ 3Y ago: -41.4%

Piotroski

5/9

Moderate

Phreesia, Inc. (PHR) has delivered a dismal total return of -62.2% over the past year, vastly underperforming the S&P 500 by an excess loss of 85.8%, reflecting both market sentiment and operational headwinds. Yet the company’s top‑line is expanding at a healthy pace, with revenue up 14.5% YoY to $481 M and a 3‑year CAGR of 19.6%, supported by a robust gross margin of nearly 68%. Profitability remains razor‑thin—operating income is negative (-1.38%) and net margin sits at only 0.48%—but free cash flow conversion is strong, delivering a 14.1% FCF margin and operating cash flow that exceeds net income by 34%, indicating cash generation despite slim earnings. The balance sheet is relatively sound: a current ratio of 1.53 and low leverage (D/E = 0.30) provide liquidity cushions, though an Altman Z‑score of 0.7 signals distress risk. Overall, the juxtaposition of rapid revenue growth with marginal profitability and elevated equity volatility creates a high‑risk, potentially upside‑biased thesis if margin expansion can be realized.

✅ Strengths

Revenue is accelerating at a 14.5% YoY rate to $481 M, driven by a 19.6% three‑year CAGR, which demonstrates strong market demand and scalability of Phreesia's platform.
Free cash flow margin stands at 14.1%, and operating cash flow exceeds net income by 34%, indicating the business can generate cash even with thin earnings—a buffer for future investments or debt repayment.
The capital structure is conservative, with a debt‑to‑equity ratio of only 0.30 and a current ratio of 1.53, providing ample liquidity to weather short‑term shocks.

⚠️ Risks

Equity performance has been volatile (volatility 58.9%) and the stock is down -62.2% YTD, reflecting investor skepticism that may limit access to cheap capital.
Operating profitability is negative (-1.38% operating margin) and ROIC is -1.79%, indicating the firm is not yet generating returns above its cost of capital, which could erode cash reserves if growth stalls.
The Altman Z‑score of 0.7 flags potential distress; combined with a negative interest coverage ratio (-1.0x), any deterioration in cash flow could trigger covenant breaches or refinancing challenges.

PHR

Related Reports

Visit finexus.net/reports for Valuation, Return & Risk, and other reports

Report written 2026-06-08 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.